Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2012-06-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia
NCT02640911
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
NCT02192723
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
NCT00237861
Validating and Optimizing Model of Antipsychotics Selection
NCT03237052
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
NCT01057849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
risperidone
low dosage of antipsychotic drug
risperidone
Risperdal tablets
olanzapine
low doseage of antipsychotic
olanzapine
olanzapine tablets
quetiapine
low doseage of antipsychotic
Quetiapine
quetiapine tablets
aripiprazole
low doseage of antipsychotic
Aripiprazole
Aripiprazole tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
risperidone
Risperdal tablets
olanzapine
olanzapine tablets
Quetiapine
quetiapine tablets
Aripiprazole
Aripiprazole tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 16-30 years
* fitted one of the following Criteria: Psychosis-risk Syndromes (COPS-SIPS) or Psychotic Syndrome (POPS-SIPS) or DSM-IV diagnosis of schizophreniform disorder
Exclusion Criteria
* symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use;
* neurological disorders or organic disorders affecting the central nervous system, substance-related disorders or mental retardation as defined by the DSM-IV criteria;
* history treatment of antipsychotic or antidepression, mood stabilizers or electroconvulsive therapy;
* diagnosed as having a serious and unstable medical condition.
16 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xiaofeng Guo
prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
xiaofeng Guo, Dr
Role: PRINCIPAL_INVESTIGATOR
the second xiangya hospitcal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Second Xiangya Hospital
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201002003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.